185 related articles for article (PubMed ID: 8229139)
1. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106.
Gaynon PS; Steinherz PG; Bleyer WA; Ablin AR; Albo VC; Finklestein JZ; Grossman NJ; Novak LJ; Pyesmany AF; Reaman GH
J Clin Oncol; 1993 Nov; 11(11):2234-42. PubMed ID: 8229139
[TBL] [Abstract][Full Text] [Related]
2. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial.
Tubergen DG; Gilchrist GS; O'Brien RT; Coccia PF; Sather HN; Waskerwitz MJ; Hammond GD
J Clin Oncol; 1993 Mar; 11(3):527-37. PubMed ID: 8445428
[TBL] [Abstract][Full Text] [Related]
3. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
[TBL] [Abstract][Full Text] [Related]
4. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group.
Nachman J; Sather HN; Cherlow JM; Sensel MG; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1998 Mar; 16(3):920-30. PubMed ID: 9508174
[TBL] [Abstract][Full Text] [Related]
5. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report.
Tubergen DG; Gilchrist GS; O'Brien RT; Coccia PF; Sather HN; Waskerwitz MJ; Hammond GD
J Clin Oncol; 1993 Mar; 11(3):520-6. PubMed ID: 8445427
[TBL] [Abstract][Full Text] [Related]
6. Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children's Cancer Study Group Study CCG-193P.
Gaynon PS; Bleyer WA; Steinherz PG; Finklestein JZ; Littman PS; Miller DR; Reaman GH; Sather HN; Hammond GD
Am J Pediatr Hematol Oncol; 1988; 10(1):42-50. PubMed ID: 3056061
[TBL] [Abstract][Full Text] [Related]
7. Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features. Early conclusions of study CCG-106 by the Childrens Cancer Study Group.
Gaynon PS; Steinherz PG; Bleyer WA; Ablin AR; Albo VC; Finklestein JZ; Grossman NJ; Littman PS; Novak LT; Pyesmany AF
Lancet; 1988 Oct; 2(8617):921-4. PubMed ID: 2902379
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
[TBL] [Abstract][Full Text] [Related]
9. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G
J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
[TBL] [Abstract][Full Text] [Related]
10. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
11. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
12. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.
Nachman JB; Sather HN; Sensel MG; Trigg ME; Cherlow JM; Lukens JN; Wolff L; Uckun FM; Gaynon PS
N Engl J Med; 1998 Jun; 338(23):1663-71. PubMed ID: 9614257
[TBL] [Abstract][Full Text] [Related]
13. Treatment of overt isolated testicular relapse in children on therapy for acute lymphoblastic leukemia. A report from the Childrens Cancer Group.
Finklestein JZ; Miller DR; Feusner J; Stram DO; Baum E; Shina DC; Johnson DG; Gyepes MT; Hammond GD
Cancer; 1994 Jan; 73(1):219-23. PubMed ID: 8275428
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
[TBL] [Abstract][Full Text] [Related]
16. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study.
Barredo JC; Devidas M; Lauer SJ; Billett A; Marymont M; Pullen J; Camitta B; Winick N; Carroll W; Ritchey AK
J Clin Oncol; 2006 Jul; 24(19):3142-9. PubMed ID: 16809737
[TBL] [Abstract][Full Text] [Related]
17. Association of delivered drug dose and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features.
Gaynon PS; Steinherz PG; Bleyer WA; Finklestein JZ; Miller DR; Reaman GH; Sather HN; Hammond GD
Med Pediatr Oncol; 1991; 19(4):221-7. PubMed ID: 2056967
[TBL] [Abstract][Full Text] [Related]
18. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
Heath JA; Steinherz PG; Altman A; Sather H; Jhanwar S; Halpern S; Pieters R; Shah N; Steinherz L; Tannous R; Terry W; Trigg ME;
J Clin Oncol; 2003 Apr; 21(8):1612-7. PubMed ID: 12697887
[TBL] [Abstract][Full Text] [Related]
19. Duration of hospitalization as a measure of cost on Children's Cancer Group acute lymphoblastic leukemia studies.
Gaynon PS; Bostrom BC; Hutchinson RJ; Lange BJ; Nachman JB; Steinherz PG; Sensel MG; Lee MK; Stram DO; Sather HN
J Clin Oncol; 2001 Apr; 19(7):1916-25. PubMed ID: 11283123
[TBL] [Abstract][Full Text] [Related]
20. Three versus five years of maintenance therapy are equivalent in childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group.
Miller DR; Leikin SL; Albo VC; Sather H; Hammond GD
J Clin Oncol; 1989 Mar; 7(3):316-25. PubMed ID: 2645385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
